Pipeline

Product

Pre-clinical

Phase I

Phase II


MB-101 IL13Rα2-specific CAR

Glioblastoma
68%

MB-102 CD123 CAR

Acute Myeloid Leukemia & Blastic Plasmacytoid Dendritic Cell Neoplasm
63%

MB-103 HER2 CAR

Glioblastoma Multiforme
52%

MB-104 CS1 CAR

Multiple Myeloma
40%

MB-105 PSCA CAR

Prostate, Pancreatic, Gastric & Bladder Cancers
40%

MB-106 CD20 CAR

B-cell non-Hodgkin Lymphoma
63%

MB-107 XSCID Gene Therapy

X-linked Severe Combined Immunodeficiency
78%